## Paola A Marignani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1471323/publications.pdf

Version: 2024-02-01

394421 377865 2,154 36 19 34 citations g-index h-index papers 38 38 38 3679 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO Journal, 2000, 19, 6778-6791.	7.8	623
2	Multiple Phosphoinositide 3-Kinase-Dependent Steps in Activation of Protein Kinase B. Molecular and Cellular Biology, 2002, 22, 6247-6260.	2.3	313
3	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis, 2015, 36, S254-S296.	2.8	239
4	LKB1 Associates with Brg1 and Is Necessary for Brg1-induced Growth Arrest. Journal of Biological Chemistry, 2001, 276, 32415-32418.	3.4	103
5	Vav2 is required for cell spreading. Journal of Cell Biology, 2001, 154, 177-186.	5.2	93
6	Association of Protein Kinase $\hat{C14}$ with Type II Phosphatidylinositol 4-Kinase and Type I Phosphatidylinositol-4-phosphate 5-Kinase. Journal of Biological Chemistry, 1998, 273, 23126-23133.	3.4	91
7	Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3. Oncogene, 2017, 36, 5709-5721.	5.9	81
8	Acyl Chain Dependence of Diacylglycerol Activation of Protein Kinase C Activityin Vitro. Biochemical and Biophysical Research Communications, 1996, 225, 469-473.	2.1	66
9	LKB1, the multitasking tumour suppressor kinase. Journal of Clinical Pathology, 2005, 58, 15-19.	2.0	58
10	Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. Carcinogenesis, 2015, 36, S2-S18.	2.8	55
11	Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells. Cancer Biology and Therapy, 2009, 8, 2054-2062.	3.4	43
12	Target Gene Therapy for α-Fetoprotein-Producing Hepatocellular Carcinoma by E1B55k-Attenuated Adenovirus. Biochemical and Biophysical Research Communications, 2001, 282, 529-535.	2.1	40
13	LKB1 Catalytic Activity Contributes to Estrogen Receptor α Signaling. Molecular Biology of the Cell, 2009, 20, 2785-2795.	2.1	36
14	Loss of lkb1 Expression Reduces the Latency of ErbB2-Mediated Mammary Gland Tumorigenesis, Promoting Changes in Metabolic Pathways. PLoS ONE, 2013, 8, e56567.	2.5	34
15	LKB1 Catalytically Deficient Mutants Enhance Cyclin D1 Expression. Cancer Research, 2007, 67, 5622-5627.	0.9	33
16	Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice. Oncolmmunology, 2016, 5, e1151591.	4.6	29
17	Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer. Cancers, 2021, 13, 2922.	3.7	29
18	Omega-3 polyunsaturated fatty acid promotes the inhibition of glycolytic enzymes and mTOR signaling by regulating the tumor suppressor LKB1. Cancer Biology and Therapy, 2013, 14, 1050-1058.	3.4	24

#	Article	IF	CITATIONS
19	Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss. Oncotarget, 2014, 5, 12738-12752.	1.8	22
20	Collagen phagocytosis is regulated by the guanine nucleotide exchange factor Vav2. American Journal of Physiology - Cell Physiology, 2008, 295, C130-C137.	4.6	18
21	Molecular profiling of non-small cell lung cancer. PLoS ONE, 2020, 15, e0236580.	2.5	17
22	Novel splice isoforms of STRADÎ $\pm$ differentially affect LKB1 activity, complex assembly and subcellular localization Cancer Biology and Therapy, 2007, 6, 1627-1631.	3.4	16
23	Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response. Frontiers in Immunology, 2018, 9, 1894.	4.8	15
24	Regulation of cell surface protease receptor \$100A10 by retinoic acid therapy in acute promyelocytic leukemia (APL)ã~†. Cell Death and Disease, 2018, 9, 920.	6.3	13
25	Single-cell RNA sequencing for the identification of early-stage lung cancer biomarkers from circulating blood. Npj Genomic Medicine, 2021, 6, 87.	3.8	11
26	Formation of second messenger diradylglycerol in murine peritoneal macrophages is altered after in vivo (n-3) polyunsaturated fatty acid supplementation. Journal of Nutrition, 1995, 125, 3030-40.	2.9	10
27	The Tumor Suppressor Kinase LKB1: Metabolic Nexus. Frontiers in Cell and Developmental Biology, 2022, 10, 881297.	3.7	9
28	S100A10 Has a Critical Regulatory Function in Mammary Tumor Growth and Metastasis: Insights Using MMTV-PyMT Oncomice and Clinical Patient Sample Analysis. Cancers, 2020, 12, 3673.	3.7	8
29	The formation of diradylglycerol molecular species in murine peritoneal macrophages varies dose-dependently with dietary purified eicosapentaenoic and docosahexaenoic ethyl esters. Journal of Nutrition, 1996, 126, 2738-45.	2.9	8
30	Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR. PLoS ONE, 2021, 16, e0251080.	2.5	7
31	Prolactin-inducible EDD E3 ubiquitin ligase promotes TORC1 signalling, anti-apoptotic protein expression, and drug resistance in breast cancer cells. American Journal of Cancer Research, 2019, 9, 1484-1503.	1.4	5
32	n-3 Polyunsaturated fatty acid-induced changes in the molecular species composition of diradylglycerol in murine peritoneal macrophages remain stable during incubationex vivo. Lipids, 1996, 31, 771-776.	1.7	1
33	Single-Cell RNA Sequencing Analysis Using Fluidigm C1 Platform for Characterization of Heterogeneous Transcriptomes. Methods in Molecular Biology, 2022, , 261-278.	0.9	1
34	Adenovirus-Mediated Drug-Sensitivity Gene Therapy for Hepatocellular Carcinoma., 2000, 45, 257-269.		0
35	Abstract 2747: Loss of S100A10 gene suppresses mammary tumor progression in PyMT mouse tumor model., 2019,,.		0
36	Abstract 2747: Loss of S100A10 gene suppresses mammary tumor progression in PyMT mouse tumor model. , 2019, , .		0